Opinion|Videos|July 2, 2024
Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- A subcutaneous form of ocrelizumab may come to market later this year. How will you incorporate this into your treatment algorithms?
- Will payers evaluate coverage decisions for this therapy differently than the intravenous form?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA Clears First Alzheimer Blood Test for Adults as Young as 40
2
RSV Vaccine Shows 100% Effectiveness in COPD: Jorgen Vestbo, MD
3
5 Things to Know About the 2026 ESC Heart Failure Guidelines
4
Enlicitide, Oral PCSK9 Inhibitor, Cuts LDL 60% in CORALreef Trials
5